Oncolytics Lands Third FDA Fast Track for Pelareorep, This Time in Anal Cancer — Opening Rolling Review Path for a $1B Market With No Approved Second-Line Option

Oncolytics Biotech Inc. (Nasdaq: ONCY) received its third FDA Fast Track designation for pelareorep on July 20, 2026 — this one for pelareorep combined with a checkpoint inhibitor in patients with inoperable, locally recurrent, or metastatic squamous cell carcinoma of the anal canal who have progressed on, or were intolerant to, one or more prior lines of systemic therapy.

The designation is the company's third in gastrointestinal oncology. The FDA previously granted Fast Track to pelareorep in KRAS-mutated metastatic colorectal cancer in February 2026 and in pancreatic cancer in late 2022, per the company's July 20, 2026 news release on GlobeNewswire.

What the designation unlocks is concrete: more frequent FDA interactions throughout development, rolling review of a future Biologics License Application, and eligibility for Priority Review if applicable, per the same release. The April 2026 FDA meeting, which the company has said provided clarity on a potential registrational pathway, preceded the designation.

CEO Jared Kelly framed the moment this way: "This Fast Track designation represents another important regulatory milestone for Oncolytics and reflects the significant progress we have made over the past twelve months in advancing pelareorep toward potential registration."

The clinical hook is a 30% objective response rate — 6 of 20 evaluable patients — reported from the GOBLET study as of October 2025, per Cancer Network's coverage. In a disease the company describes as a $1 billion market with no approved options after first-line therapy, that number is the data pillar the designation rests on.

Pelareorep is an oncolytic virus; in this program it runs alongside a checkpoint inhibitor. Oncolytics has an agreement with Roche Holding AG to supply atezolizumab for use in the company's ongoing sponsored studies, per Yahoo Finance.

Three trading days after the announcement, ONCY was quiet. On July 23, 2026, the stock traded between $0.81 and $0.86, sitting at $0.82 at last check, per Robinhood market data. Volume was 172,580 shares against an average daily volume of 2.2 million, per the same source. Market capitalization at $0.82 per share is reported at $95.65 million, with 101,246,185 shares outstanding, per TipRanks.

Operating cash flow over the last twelve months was -$24.65 million and free cash flow was -$24.68 million, per Yahoo Finance.

What's next, per the July 20, 2026 release: the company intends to advance pelareorep toward a registrational study in anal canal carcinoma, with the April 2026 FDA meeting having already shaped that pathway. No timeline or trial design was detailed in the release.